Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Intangibles (2023 - 2025)

Rein Therapeutics (RNTX) has disclosed Intangibles for 3 consecutive years, with $42.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles fell 46.72% to $42.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $42.2 million, a 46.72% decrease, with the full-year FY2024 number at $42.2 million, down 46.72% from a year prior.
  • Intangibles was $42.2 million for Q3 2025 at Rein Therapeutics, roughly flat from $42.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $79.2 million in Q4 2023 to a low of $42.2 million in Q4 2024.
  • A 3-year average of $60.7 million and a median of $60.7 million in 2023 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 46.72% in 2024; the steepest drop was 46.72% in 2024.
  • Rein Therapeutics' Intangibles stood at $79.2 million in 2023, then crashed by 46.72% to $42.2 million in 2024, then changed by 0.0% to $42.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Intangibles are $42.2 million (Q3 2025), $42.2 million (Q2 2025), and $42.2 million (Q1 2025).